Let's be honest: if you told most VCs in early 2026 that a nine-year-old healthcare data company was going to raise $40 million from CVS Health Ventures, they'd have asked what's wrong with you.
Pre-AI SaaS startups are having a rough time. No sugarcoating that. Valuations cratered. IPO windows slammed shut. The kind of investor enthusiasm that used to come with a free Slack ping and a same-day calendar invite? Now you're lucky if you get a reply in a week.
But here's what the broader narrative misses: not every SaaS company is built on the same thing. And when the easy money dries up, you find out which companies were actually building something durable versus which ones were just riding a wave of cheap capital and bigger valuations.
H1, a healthcare data platform that tracks physician behavior on a global scale, just closed $40 million from CVS Health Ventures. This wasn't a down round. It wasn't some desperate bridge to keep the lights on. It was strategic capital from one of the largest health systems in America — and it tells a story about where real value still hides that most people aren't paying attention to.
H1 Didn't Need This Money. That's the Point.
Ariel Katz, H1's co-founder and CEO, said something that should make every founder listening closely: the company didn't even ask for this round.
Last year, H1 hit cash flow and EBITDA profitability. This year, it's forecasting over 40% growth. Most startups raise when they're running out of runway, trying to cut a loss, or delaying the inevitable waterfall. H1 raised because CVS Health Ventures came knocking.
"It was hard to refuse," Katz told TechCrunch. And honestly? You can hear the conviction in that.
Think about what's actually happening here. H1 is a health data company whose core product is deep, structured insight into physician behavior globally — prescribing patterns, patient volumes, network affiliations. CVS Health Ventures is one of the largest healthcare companies in the world. They need exactly that data to function smarter.
So this wasn't a traditional VC round at all. It was corporate synergy at scale. CVS isn't buying H1 to prop it up — they're buying access to a dataset that gives them an edge they can't build alone.
"I Don't Worry About Claude Doing What We Do"
Katz wasn't being modest when he told TechCrunch he doesn't worry about AI threatening H1's business model. His exact words: "I don't worry about Claude ever doing what we do."
Now, before you write that off as founder bravado — and sure, there's some of that — his point actually holds water. H1 doesn't compete with AI. It feeds it.
Here's the distinction most people miss: most AI startups optimize around code, interfaces, or chat. All of those things can be auto-generated. H1's product is a dataset — the real-time behavior, prescribing patterns, patient volumes, and network affiliations of physicians around the world.
That's not a feature you can code. It's infrastructure you have to gather — over years, through hundreds of partnerships, with strict compliance guardrails that would make most tech companies' heads spin.
"What AI cannot easily replicate," Katz added, "is a company that is a data provider at its core."
And CVS Health Ventures clearly agreed. Because for them, access to H1's data means fewer wasted drug launches, better care path recommendations, and smarter provider segmentation. It turns raw data into decisions — at scale.
TechCrunch's Marina Temkin called this a "self-serving viewpoint" — and yeah, it is. H1's entire business model is built on selling detailed information about doctors to pharma companies, hospital systems, and health insurers. But self-serving doesn't mean wrong.
The 2021 Bubble Didn't Kill H1. It Made Them Tough.
Here's the part of this story that doesn't get enough airtime:
In November 2021 — at the absolute peak of the pandemic-fueled tech bubble — H1 raised $100 million from Altimeter Capital at a $750 million valuation.
Sound familiar? It should. That was just before everything cracked.
For most startups that raised in that window, the aftermath was brutal: down rounds, layoffs, restructurings, and a lot of painful pivots. H1 went through the same squeeze.
But here's what they did differently: instead of chasing growth at all costs, they doubled down on profitability. They stopped pretending the easy money was coming back and started making hard decisions. They also began acquiring smaller competitors and complementary data assets, folding them into their platform with what Katz would call "surgical precision."
That's why the CVS round isn't surprising — it's inevitable. A business that survived 2022 and 2023 without raising additional capital, stayed profitable, and grew anyway? That's a company that deserves its headline.
What This Actually Means for the Market
Let's be clear about what H1's raise signals — and more importantly, what it doesn't:
It does not signal a return to 2021. The era of throwing money at vague narratives and hoping for the best is over.
What it does confirm: not all SaaS startups are created equal, and not every data business is vulnerable to AI disruption.
In fact, if you build the right kind of data SaaS — something grounded in real-world transactions, relationships, and regulation — you may end up being more valuable in an AI world, not less. Because AI needs data to function, and the companies that control unique, hard-to-duplicate datasets become essential partners rather than competitors.
CVS didn't invest in H1 hoping to replace it. They invested because H1 gives them something they can't build on their own.
The bar is higher now. But the prize for companies that clear it? Higher still.
The Data Moat That AI Can't Cross
There's a specific kind of defensibility that H1 has built, and it's the kind that doesn't show up on a typical competitive analysis.
Most SaaS companies defend themselves with features, integrations, or switching costs. H1 defends itself with something far more fundamental: years of accumulated, structured data about physician behavior that no amount of AI can generate from scratch.
Think about it. You could build the best AI model in the world, but if you don't have access to real-time prescribing patterns across thousands of hospital systems, if you haven't spent nine years building partnerships with health networks worldwide, if you don't have the compliance infrastructure to handle protected health information — then your model is only as good as the data it's trained on.
And H1 is the data.
This is why Katz's claim that AI companies might become H1's customers rather than competitors isn't as far-fetched as it sounds. The companies building the most powerful AI models need training data. They need real-world signals. They need someone who's already done the unglamorous work of gathering, structuring, and maintaining massive datasets.
That's not a vulnerability. That's a position of strength.
The Strategic Logic Behind CVS's Move
CVS Health Ventures leading this round isn't random. It's a calculated move that reveals a lot about where healthcare is heading.
CVS/Aetna is one of the largest vertically integrated health systems in America. They have pharmacies, insurance plans, hospital systems, and a massive provider network. But having all those pieces doesn't mean you know how to use them optimally.
H1's data gives CVS the ability to understand physician behavior at a granular level — who's prescribing what, where patients are going, which providers are performing best, where the gaps in care actually are. That's not just useful information. It's a competitive weapon.
And by investing $40 million rather than acquiring outright, CVS gets access to H1's full dataset and platform without the integration headaches that come with a full acquisition. They get the strategic advantage without the operational burden.
It's the kind of move that makes you realize: in a world where AI is reshaping everything, the companies that control unique data assets are the ones writing the rules.
The Bigger Picture: What Founders Should Take Away
If you're a founder building in the current market, H1's story offers some uncomfortable but necessary lessons.
First: profitability matters more than growth metrics. H1 didn't raise this round because they were burning cash and needed runway. They raised it because they'd proven they could stand on their own — and that made them more attractive to strategic investors.
Second: data is the new moat. Not features. Not user experience. Not even network effects in the traditional sense. The companies that will survive — and thrive — are those building unique, hard-to-replicate data assets.
Third: strategic investors can be more valuable than financial ones. A $40 million check from a VC who wants a 10x return in five years is nice. A $40 million investment from CVS Health Ventures, who sees H1's data as essential to their own strategy, is something else entirely.
The market for pre-AI SaaS startups isn't dead. It's just evolved. And the companies that understood that early — like H1 — are the ones reaping the rewards.
